MGAT4 family member CGenealiases: GNTIVH · HGNT-IV-H
Q-omics provides the consensus-scored MGAT4C profile across patient tissues and cancer cell-line models. MGAT4C expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MGAT4C is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MGAT4C RNA expression shows 13,239 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where MGAT4C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGAT4C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGAT4C survival associations across molecular data types. MGAT4C RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGAT4C RNA expression–survival associations across cancer types. High MGAT4C expression shows unfavorable associations in KIRP, BLCA, ACC, UCEC and READ, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MGAT4C RNA expression.
This table summarizes MGAT4C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MGAT4C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGAT4C shows lower tumor expression in COAD, KIRC, KICH, KIRP and READ and higher tumor expression in HNSC. The COAD box plot shows higher MGAT4C RNA expression in normal versus tumor tissue (log2 FC = −0.105, t-test p < 0.001).
This table shows molecular features associated with MGAT4C in patient tissues and cancer cell lines. In patient samples, MGAT4C shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MGAT4C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
